Evaluation of Benztropine for Cocaine Craving - 2

This study has been completed.

First Received: September 20, 1999 Last Updated: June 23, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Department of Veterans Affairs
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000333

Purpose

The purpose of this study is to compare the efficacy of benztropine (or DA reuptake inhibitor) with atropine and placebo in affecting stimulated craving to cocaine cues.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Benztropine	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Evaluation of Efficacy of Benztropine for Cocaine Craving

Resource links provided by NLM:

Drug Information available for: Cocaine hydrochloride Benztropine Benzatropine methanesulfonate

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Stimulated and non-stimulated craving

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	22 Years to 48 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000333

Locations

United States, District of Columbia
Washington DC VA
Washington, District of Columbia, United States, 20422

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Department of Veterans Affairs

Investigators

Principal Investigator:

Steven Deutsch, M.D.

Washington DC VA

More Information

No publications provided

Study ID Numbers:	NIDA-3-0009-2, Y01-3-0009-2
Study First Received:	September 20, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000333 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors
Cocaine-Related Disorders
Parasympatholytics
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Cholinergic Antagonists
Anti-Dyskinesia Agents
Physiological Effects of Drugs
Disorders of Environmental Origin
Antiparkinson Agents

Cholinergic Agents
Pharmacologic Actions
Muscarinic Antagonists
Mental Disorders
Autonomic Agents
Therapeutic Uses
Substance-Related Disorders
Dopamine Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Benztropine

ClinicalTrials.gov processed this record on February 08, 2010